Market Cap | 1.73B | P/E | 10.82 | EPS this Y | 103.70% | Ern Qtrly Grth | - |
Income | 9.21M | Forward P/E | 12.24 | EPS next Y | 62.50% | 50D Avg Chg | 3.00% |
Sales | 400.56M | PEG | 0.23 | EPS past 5Y | 6.41% | 200D Avg Chg | 1.00% |
Dividend | N/A | Price/Book | 2.45 | EPS next 5Y | 72.58% | 52W High Chg | -12.00% |
Recommedations | 2.00 | Quick Ratio | 3.60 | Shares Outstanding | 159.74M | 52W Low Chg | 14.00% |
Insider Own | 1.69% | ROA | 14.93% | Shares Float | 131.89M | Beta | 0.49 |
Inst Own | 109.54% | ROE | - | Shares Shorted/Prior | 11.61M/14M | Price | 11.14 |
Gross Margin | 67.95% | Profit Margin | 2.30% | Avg. Volume | 2,016,201 | Target Price | 11.43 |
Oper. Margin | 29.07% | Earnings Date | Nov 7 | Volume | 821,302 | Change | -0.98% |
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Emany Sravan Kumar | SVP, Chief Financial.. SVP, Chief Financial Officer | Sep 15 | Buy | 8.32 | 36,072 | 300,119 | 188,730 | 09/18/23 |
MCCOURT Thomas A | Chief Executive Offi.. Chief Executive Officer | May 30 | Sell | 10.70 | 26,632 | 284,962 | 758,284 | 06/01/23 |
Silver Ronald | Principal Accounting.. Principal Accounting Officer | Feb 27 | Sell | 11.36 | 5,978 | 67,910 | 98,491 | 03/01/23 |
Rickard Jason | SVP, Chief Operating.. SVP, Chief Operating Officer | Feb 27 | Sell | 11.36 | 34,175 | 388,228 | 332,648 | 03/01/23 |
MCCOURT Thomas A | Chief Executive Offi.. Chief Executive Officer | Feb 27 | Sell | 11.36 | 61,231 | 695,584 | 681,354 | 03/01/23 |
Shetzline Michael | CMO,SVP,Head-Res&Dru.. CMO,SVP,Head-Res&Drug | Feb 27 | Sell | 11.36 | 19,322 | 219,498 | 261,586 | 03/01/23 |
John Minardo | Chief Legal Officer Chief Legal Officer | Feb 27 | Sell | 11.36 | 6,697 | 76,078 | 133,738 | 03/01/23 |
Davis Andrew | SVP, Chief Business.. SVP, Chief Business Officer | Feb 27 | Sell | 11.36 | 3,573 | 40,589 | 151,396 | 03/01/23 |
Currie Mark G | Director Director | Aug 11 | Sell | 11.78 | 70,000 | 824,600 | 521,758 | 08/15/22 |
Rickard Jason | SVP, Chief Operating.. SVP, Chief Operating Officer | Aug 08 | Sell | 11.65 | 47,477 | 553,107 | 376,730 | 08/10/22 |
Rickard Jason | SVP, Chief Operating.. SVP, Chief Operating Officer | Aug 08 | Option | 11.65 | 18,041 | 210,178 | 394,771 | 08/10/22 |
Currie Mark G | Director Director | Jun 07 | Option | 11.65 | 190,383 | 2,217,962 | 782,141 | 06/09/22 |
Currie Mark G | Director Director | Jun 07 | Sell | 12.01 | 190,383 | 2,286,500 | 591,758 | 06/09/22 |
- | - - | Mar 10 | Buy | 10.42 | 225,000 | 2,344,500 | 16,390,000 | 03/10/21 |
DENNER ALEXANDER J | Director Director | Mar 02 | Buy | 9.45 | 1,350,000 | 12,757,500 | 15,390,000 | 03/02/21 |
Rickard Jason | SVP, Chief Operating.. SVP, Chief Operating Officer | Mar 02 | Sell | 9.11 | 13,651 | 124,361 | 306,682 | 03/02/21 |
MacDonald Kelly | Chief Accounting Off.. Chief Accounting Officer | Dec 08 | Option | 9.12 | 5,639 | 51,428 | 98,680 | 12/08/20 |
MacDonald Kelly | Chief Accounting Off.. Chief Accounting Officer | Dec 08 | Sell | 12.5 | 5,639 | 70,488 | 93,041 | 12/08/20 |
Kilroy Conor | SVP, GC & Secretary SVP, GC & Secretary | Nov 10 | Sell | 10.92 | 836 | 9,129 | 128,833 | 11/10/20 |
Consylman Gina | SVP, CFO & Treasurer SVP, CFO & Treasurer | Nov 10 | Sell | 10.92 | 1,415 | 15,452 | 269,699 | 11/10/20 |